Pharmaceutical companies operating in Russia must localise personal data of Russian users under 152-FZ. Sector-specific rules apply. Make an enquiry.
Foreign pharmaceutical companies operating in Russia are required to localise the personal data of Russian users — meaning that the primary database processing such data must be stored on servers physically located within Russia. This obligation arises under Russian data protection legislation and applies irrespective of whether the company is incorporated in Russia or operates through a foreign entity. Non-compliance exposes the company to regulatory action by Roskomnadzor, including the risk of website blocking or restrictions on data processing activities.
The pharmaceutical sector does not benefit from a general sector-specific exemption to the localisation requirement. In practice, this affects a wide range of data-handling operations common to the industry: patient registries, clinical trial participant records, employee data, and the personal data of Russian healthcare professionals collected through medical representative activities. Each of these processing activities must satisfy the localisation standard to the extent they involve personal data of individuals in Russia. Companies managing cross-border clinical trial programmes should be particularly attentive to how data flows are structured: transferring personal data outside Russia remains permissible under certain conditions — including where the destination country is recognised as providing adequate protection, or where the data subject has consented — but the primary database must first be localised in Russia.
For in-house counsel managing Russian compliance, the practical priority is an audit of data flows specific to the pharmaceutical operating model — identifying which processing activities involve Russian personal data, which servers are in scope, and whether cross-border transfer arrangements meet current requirements. Companies that have not conducted such a review face a gap that Roskomnadzor inspections have increasingly targeted in regulated sectors.
Our Data Protection practice advises foreign pharmaceutical companies on 152-FZ compliance, data flow mapping, and regulatory engagement with Roskomnadzor. Related guidance is available at Data Localisation Obligations for Foreign Companies and Ministry of Finance Guidance on Data Localisation.
Make an enquiry — info@vetrovpartners.com |
— Elena Pavlova Associate, Vetrov & Partners vetrovpartners.com/pavlova/
Elena Pavlova advises foreign companies on Russian data protection law (Federal Law No. 152-FZ), regulatory compliance, and distribution arrangements. She assists in due diligence for cross-border transactions and supports the firm's corporate and IP practices.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry